Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment

Annals of Oncology

Volumn 12, Issue 9, 2001, Pages 1307-1311

  Rueffer, U ^a   Breuer, K ^a   Josting, A ^a   Lathan, B ^a   Sieber, M ^a   Manzke, O ^a   Grotenhermen, F J ^a   Tesch, H ^b   Bredenfeld, H ^a   Koch, P ^b   Nisters Backes, H ^a   Wolf, J ^a   Engert, A ^a   Diehl, V ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b SCHWARZWALD BAAR KLINIKUM   (Germany)

Author keywords

Follicle stimulating hormone; Hodgkin's disease; Luteinising hormone; Male fertility; Prognostic factors

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; GONADOTROPIN; IFOSFAMIDE; LUTEINIZING HORMONE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ARTICLE; AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DRUG TOXICITY; ERYTHROCYTE SEDIMENTATION RATE; FOLLITROPIN BLOOD LEVEL; GONAD DYSFUNCTION; HODGKIN DISEASE; HORMONE ACTION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALE FERTILITY; MALE INFERTILITY; MULTIVARIATE ANALYSIS; OLIGOSPERMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RISK; SEMEN ANALYSIS; SPERM; SPERMATOZOON COUNT; SYMPTOM; WORLD HEALTH ORGANIZATION;

EID: 0034772830     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012464703805     Document Type: Article

References (35)

1. The management of Hodgkin's disease: Half a century of change
2. Second cancer after the treatment for Hodgkin's disease: A report from the international database on Hodgkin's disease
3. Second cancer risk following Hodgkin's disease: A 20-year follow-up study
4. Non-Hodgkin-Lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group (GHSG): Incidence, treatment and prognosis
5. Thyreoid, pulmonary, and cadiac sequelae after treatment for Hodgkin's disease
6. Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin's disease treated by MOPP, ABVD, or MOPP alterating with ABVD
7. Male gonadal dysfunction in Hodgkin's disease: A prospective study
8. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease
9. Cyclical combination chemotherapy and gonadal function: Retrospective study in males
10. Testicular dysfunction in untreated Hodgkin's disease
11. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male
12. Evaluation of semen and pituary gonadotropin function in men with untreated Hodgkin's disease
13. Testicular dysfunction in Hodgkin's disease - Before and after treatment
14. Empfehlungen zur Nomenklatur in der Andrologie
15. Decline in semen quality among fertile men in Paris during the past 20 years
16. High and unchanged sperm counts of Finnish men
17. Value of clinical diagnosis in predicting the quality of cryopreserved sperm from cancer patients
18. Autoconservation de sperme et toxicité gonadique après traitement pour lymphome non hodgkinen. Expérience de l'institut Gustave-Roussy de 1980 a 1993
19. Circulating inhibin and testosterone levels in men with critical illness
20. Fertility after chemotherapy for testicular cancer
21. Semen analysis in testicular cancer and Hodgkin's disease: Pre- and post-treatment findings and implications for cryopreservation
22. Semen analysis in Hodgkin's disease before the onset of treatment
23. Cytokines stimulate lipid membrane peroxidation of human sperm
24. Seminal cytokine concentrations (IL-1β, IL-2, IL-6, sR IL2, sR IL-6), semen parameters and blood hormonal status in male infertility
25. Cytokine levels in the seminal plasma of infertile males
26. Distinct expression levels of cytokines and soluble cytokine receptors in seminal plasma of fertile and infertile men
27. Systemic interleukin-1 alpha and interleukin-2 secretion in response to acute stress and to corticotropin-releasing hormone in humans
28. High concentration of soluble interleukin-2 receptors in ejaculate with low sperm motility
29. Pre- and posttreatment testicular dysfunction in Hodgkin's disease (HD)
30. Gonadal function in Hodgkin's disease: Long-term follow-up of chemotherapy
31. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. Disease, metabolism and reproduction in the toxic response to drugs and other chemicals
32. Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy
33. Long-term gonadal dysfunction and it's impact on bone mineralisation in patients following COPP/ABVD chemotherapy for Hodgkin's disease